'Miss­ing link': Bay­er, Morn­ing­side help cat­a­pult a new kind of de­liv­ery tech to cell and gene ther­a­py

Robert Mill­man co-found­ed and led Sem­ma Ther­a­peu­tics as CEO while al­so a man­ag­ing di­rec­tor of MPM Cap­i­tal. By the time he left the stem cell ther­a­py pi­o­neer — two years be­fore it would be sold to Ver­tex — he had left VC life be­hind.

In­stead, he went around scout­ing new tech­nolo­gies, vis­it­ing with tech trans­fer of­fices and aca­d­e­mics in the Boston/Cam­bridge area to find wor­thy ideas that could ben­e­fit from his IP ex­per­tise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.